Cargando...
How Long is Enough – Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer
Trastuzumab administered in combination with various chemotherapy regimens has led to outstanding improvements in both disease-free survival and overall survival. So far, thousands of patients have been treated in this way which has proven to be reasonably safe, with cardiac events being the predomi...
Gardado en:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
S. Karger GmbH
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3808227/ https://ncbi.nlm.nih.gov/pubmed/24415979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000354697 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|